Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Fly Intel: Top five weekend stock stories » 20:11
01/17/22
01/17
20:11
01/17/22
20:11
GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

, UN

Unilever

$60.50 /

+ (+0.00%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

, T

AT&T

$27.18 /

+0.37 (+1.38%)

, VZ

Verizon

$53.29 /

-0.24 (-0.45%)

, AAL

American Airlines

$18.50 /

-0.84 (-4.34%)

, DAL

Delta Air Lines

$40.31 /

-1.15 (-2.77%)

, UAL

United Airlines

$46.74 /

-1.39 (-2.89%)

, LUV

Southwest

$45.84 /

+0.045 (+0.10%)

, ANGI

Angi Inc.

$8.20 /

+0.29 (+3.67%)

, ABNB

Airbnb

$163.96 /

-2.04 (-1.23%)

, ETSY

Etsy

$163.80 /

-2.75 (-1.65%)

, UBER

Uber

$41.53 /

-1.305 (-3.05%)

, VIAC

ViacomCBS

$36.83 /

+0.64 (+1.77%)

, VIACA

ViacomCBS

$41.18 /

+0.78 (+1.93%)

, FCX

Freeport McMoRan

$44.08 /

-0.26 (-0.59%)

, TTWO

Take-Two

$152.57 /

-2.2 (-1.42%)

, RDS.A

Royal Dutch Shell

$50.06 /

+0.83 (+1.69%)

, RDS.B

Royal Dutch Shell

$50.09 /

+0.84 (+1.71%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Unilever (UN, UL) confirms approach made to GlaxoSmithKline (GSK) and Pfizer (PFE) about GSK Consumer Healthcare. The company said that, "Unilever notes recent reporting regarding its interest in GSK Consumer Healthcare and confirms that it has approached GSK and Pfizer about a potential acquisition of the business. GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio. There can be no certainty that any agreement will be reached." Meanwhile, GlaxoSmithKline has also said in a statement that, "GlaxoSmithKline today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of GBP 50 billion comprising GBP 41.7 billion in cash and GBP 8.3 billion in Unilever shares. The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%. GSK rejected all three proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects." 2. The chief executives of major U.S. passenger and cargo carriers on Monday warned of an impending "catastrophic" aviation crisis on Wednesday when AT&T (T) and Verizon (VZ) are set to deploy new 5G service, Reuters' David Shepardson reported. The airlines warned the new C-Band 5G service could potentially make a significant number of widebody aircraft unusable and "could potentially strand tens of thousands of Americans overseas." "Unless our major hubs are cleared to fly, the vast majority of the traveling and shipping public will essentially be grounded," wrote the chief executives of American Airlines (AAL), Delta Air Lines (DAL), United Airlines (UAL), Southwest Airlines (LUV) and others. 3. Revenue for Angi's (ANGI) ads and leads business was flat in the latest quarter, even as demand for contractors surged, and the stock is down 33% over the past 12 months, Nicholas Jasinski wrote in this week's edition of Barron's. But Angi is working on a fix and the stock now looks like a bargain, the author contended. So far, investors aren't paying attention, with Angi stock trading for just 1.8 times the $2.29 billion in revenue that Wall Street expects the company to generate in 2023, the publication pointed out. That compares with Angi's five-year average of more than five times year-ahead revenue. Leading online marketplaces like Airbnb (ABNB), Etsy (ETSY), and Uber Technologies (UBER) fetch an average multiple of 6.1, Jasinski added. 4. ViacomCBS (VIAC) subsidiary Paramount Pictures' "Scream" won the Martin Luther King Jr. holiday weekend at the box office with a four-day gross of $34M. For the three-day domestic weekend, the movie earned an estimated $31M from 3,664 locations. Overseas, the slasher pic grossed $18M from 50 markets for a global cume of $52M. 5. Freeport-McMoRan (FCX), Take-Two (TTWO), and Shell (RDS.A) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
VZ Verizon
$53.29 /

-0.24 (-0.45%)

VIACA ViacomCBS
$41.18 /

+0.78 (+1.93%)

VIAC ViacomCBS
$36.83 /

+0.64 (+1.77%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

T AT&T
$27.18 /

+0.37 (+1.38%)

RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

ABNB Airbnb
$163.96 /

-2.04 (-1.23%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/17/22 Bernstein
Unilever downgraded to Underperform from Market Perform at Bernstein
01/17/22 Barclays
Unilever downgraded to Equal Weight from Overweight at Barclays
01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
UL Unilever
$54.30 /

+0.645 (+1.20%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
UN Unilever
$60.50 /

+ (+0.00%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
T AT&T
$27.18 /

+0.37 (+1.38%)

01/11/22 Citi
Citi adds Crown Castle, Switch to 'Positive Catalyst Watch List'
01/11/22 Citi
Citi adds AT&T to 'positive catalyst watch list,' keeps $29 target
01/07/22 Wells Fargo
Wells upgrades AT&T to neutral with downside risks 'more limited'
01/07/22 Wells Fargo
AT&T upgraded to Equal Weight from Underweight at Wells Fargo
VZ Verizon
$53.29 /

-0.24 (-0.45%)

01/11/22 Goldman Sachs
Verizon downgraded to Buy from Conviction Buy at Goldman Sachs
12/23/21
Fly Intel: Top five analyst initiations
12/23/21 Daiwa
Verizon initiated with a Neutral at Daiwa
AAL American Airlines
$18.50 /

-0.84 (-4.34%)

01/11/22 Morgan Stanley
American Airlines upgraded to Equal Weight from Underweight at Morgan Stanley
01/07/22 BofA
BofA upgrades Delta to Buy, thinks poor sentiment could set up bounce
01/03/22 Citi
Citi says omicron 'modest' risk to airlines, names Frontier preferred pick
12/06/21 Evercore ISI
American Airlines upgraded to In Line at Evercore ISI following 15% pullback
DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

01/14/22 Raymond James
Delta Air Lines price target lowered to $53 from $55 at Raymond James
01/14/22 Barclays
Delta Air Lines price target lowered to $45 from $50 at Barclays
01/13/22 Goldman Sachs
Delta Air Lines price target raised to $40 from $39 at Goldman Sachs
01/13/22 Susquehanna
Delta Air Lines upgraded to Positive with $50 price target at Susquehanna
UAL United Airlines
$46.74 /

-1.39 (-2.89%)

01/14/22 Barclays
United Airlines price target lowered to $52 from $58 at Barclays
01/13/22 Susquehanna
United Airlines upgraded to Positive with $60 price target at Susquehanna
01/13/22 Susquehanna
United Airlines upgraded to Positive from Neutral at Susquehanna
LUV Southwest
$45.84 /

+0.045 (+0.10%)

01/14/22 Barclays
Southwest price target lowered to $59 from $65 at Barclays
01/13/22 Susquehanna
Southwest downgraded to Neutral from Positive at Susquehanna
01/12/22 Wolfe Research
Southwest downgraded to Peer Perform from Outperform at Wolfe Research
01/12/22 Wolfe Research
Southwest downgraded to Peer Perform from Outperform at Wolfe Research
ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

01/06/22 Goldman Sachs
Angi Inc. assumed with a Buy at Goldman Sachs
12/15/21 JPMorgan
Angi Inc. price target lowered to $13 from $17 at JPMorgan
11/08/21 Piper Sandler
IAC price target raised to $168 from $158 at Piper Sandler
11/08/21 Piper Sandler
Angi Inc. price target lowered to $12 from $13 at Piper Sandler
ABNB Airbnb
$163.96 /

-2.04 (-1.23%)

01/14/22 Stifel
Expedia price target raised to $190 from $180 at Stifel
01/10/22 Piper Sandler
Airbnb downgraded to Neutral from Overweight at Piper Sandler
01/07/22 Jefferies
Airbnb assumed with a Buy at Jefferies
12/16/21 RBC Capital
Airbnb downgraded to Sector Perform at RBC Capital on 'balanced' risk-reward
ETSY Etsy
$163.80 /

-2.75 (-1.65%)

01/12/22 Stifel
Etsy price target lowered to $230 from $265 at Stifel
12/02/21 UBS
Etsy initiated with a Sell at UBS
11/24/21 Wedbush
Etsy price target raised to $310 from $264 at Wedbush
11/24/21 Citi
Etsy price target raised to $320 from $245 at Citi
UBER Uber
$41.53 /

-1.305 (-3.05%)

01/13/22 Mizuho
Regulatory trends favorable for gig economy companies, says Mizuho
01/11/22 JPMorgan
Amazon 'strong favorite' to be best performing FANG stock, JPMorgan says
01/07/22 Needham
Needham names Uber Top Pick for 2022, lowers price target to $75 from $77
01/07/22 Jefferies
Jefferies sees Lyft trailing Uber in 2022, downgrades to Hold
VIAC ViacomCBS
$36.83 /

+0.64 (+1.77%)

01/10/22 Deutsche Bank
Deutsche Bank upgrades ViacomCBS to Buy, calls top media pick
01/10/22 Deutsche Bank
ViacomCBS upgraded to Buy from Hold at Deutsche Bank
12/14/21 Macquarie
ViacomCBS price target lowered to $32 from $40 at Macquarie
10/15/21 Deutsche Bank
ViacomCBS price target lowered to $44 from $45 at Deutsche Bank
VIACA ViacomCBS
$41.18 /

+0.78 (+1.93%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

12/13/21 Stifel
Freeport McMoRan initiated with a Buy at Stifel
11/16/21 Wolfe Research
Freeport McMoRan initiated with an Outperform at Wolfe Research
10/22/21
Fly Intel: Top five analyst downgrades
10/22/21 Argus
Freeport McMoRan price target raised to $45 from $40 at Argus
TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

01/13/22 Stifel
Zynga downgraded to Hold from Buy at Stifel
01/12/22 BMO Capital
Take-Two upgraded to Outperform from Market Perform at BMO Capital
01/11/22 Truist
Zynga downgraded to Hold from Buy at Truist
01/11/22 KeyBanc
Zynga downgraded to Sector Weight from Overweight at KeyBanc
RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

01/17/22 Goldman Sachs
ConocoPhillips upgraded to Buy from Neutral at Goldman Sachs
01/07/22 Exane BNP Paribas
Royal Dutch Shell downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21 Deutsche Bank
Royal Dutch Shell price target raised to 2,038 GBp at Deutsche Bank
11/17/21 Scotiabank
Royal Dutch Shell upgraded to Outperform at Scotiabank
RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

11/17/21 Scotiabank
Shell Class B upgraded to Outperform from Sector Perform at Scotiabank
VZ Verizon
$53.29 /

-0.24 (-0.45%)

VIAC ViacomCBS
$36.83 /

+0.64 (+1.77%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

T AT&T
$27.18 /

+0.37 (+1.38%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

ABNB Airbnb
$163.96 /

-2.04 (-1.23%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

  • 29
    Jul
  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VZ Verizon
$53.29 /

-0.24 (-0.45%)

VIACA ViacomCBS
$41.18 /

+0.78 (+1.93%)

VIAC ViacomCBS
$36.83 /

+0.64 (+1.77%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

T AT&T
$27.18 /

+0.37 (+1.38%)

RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

ABNB Airbnb
$163.96 /

-2.04 (-1.23%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

VZ Verizon
$53.29 /

-0.24 (-0.45%)

VIACA ViacomCBS
$41.18 /

+0.78 (+1.93%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

T AT&T
$27.18 /

+0.37 (+1.38%)

RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

ABNB Airbnb
$163.96 /

-2.04 (-1.23%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

VZ Verizon
$53.29 /

-0.24 (-0.45%)

VIAC ViacomCBS
$36.83 /

+0.64 (+1.77%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

T AT&T
$27.18 /

+0.37 (+1.38%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ABNB Airbnb
$163.96 /

-2.04 (-1.23%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

Periodicals
Study says 4th Pfizer doze insufficient to ward off Omicron, Bloomberg reports » 15:24
01/17/22
01/17
15:24
01/17/22
15:24
PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

, BNTX

BioNTech

$196.03 /

-6.99 (-3.44%)

A fourth dose of the…

A fourth dose of the Pfizer (PFE)-BioNTech (BNTX) vaccine was insufficient to prevent infection with the omicron variant of COVID-19, Bloomberg's Daniel Avis reports, citing preliminary data from a trial in Israel released Monday. Two weeks after the start of the trial of 154 medical personnel at the Sheba Medical Center in Tel Aviv, researchers found the vaccine successfully raised antibody levels. But that only offered a partial defense against omicron, according to Gili Regev-Yochay, the trial's lead researcher. Vaccines which were more effective against previous variants offer less protection with omicron, she said. Still, those infected in the trial had only slight symptoms or none at all. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

BNTX BioNTech
$196.03 /

-6.99 (-3.44%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
BNTX BioNTech
$196.03 /

-6.99 (-3.44%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

BNTX BioNTech
$196.03 /

-6.99 (-3.44%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

BNTX BioNTech
$196.03 /

-6.99 (-3.44%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

BNTX BioNTech
$196.03 /

-6.99 (-3.44%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

BNTX BioNTech
$196.03 /

-6.99 (-3.44%)

Saturday
Hot Stocks
GSK says rejected 3 Unilever bids that 'undervalued' Consumer Healthcare unit » 16:37
01/15/22
01/15
16:37
01/15/22
16:37
GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

, UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

A press release was…

A press release was issued today by GlaxoSmithKline (GSK) to the London Stock Exchange, entitled "Update - GSK Consumer Healthcare," that states in part: "GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of GBP 50 billion comprising GBP 41.7 billion in cash and GBP 8.3 billion in Unilever shares. The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%. GSK rejected all three proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK is strongly focused on maximising value for GSK shareholders and has carefully evaluated each Unilever proposal. In doing so, the Board and its advisers assessed the proposals relative to the financial planning assessments completed to support the proposed demerger of the business in mid-2022, including the sales growth outlook set out below... The business has an exceptional portfolio of world-class, category-leading brands; global scale with footprint and distribution capability to serve more than 100 markets; strong brand building, innovation and digital capabilities; and offers a unique proposition that combines trusted science with human understanding... The business is well-positioned to sustainably grow ahead of its categories in the years to come. The fundamentals for the GBP 150 billion consumer healthcare sector are strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle class, and sizeable unmet consumer needs. Over the period 2019-2021 the Consumer Healthcare business delivered a 4% organic sales growth CAGR2 outpacing its categories and despite the adverse impact of the COVID pandemic. Superior sales growth for the business is expected to result from a strategy that puts the consumer at the heart of the business to better address every-day health and wellness needs, in particular by increasing household penetration of its leading brands and capitalising on new and emerging growth opportunities arising from innovation and the use of new technologies and digital platforms, all underpinned by continued strong execution and financial discipline. Over the medium term, superior sales growth is expected to be primarily driven by continued momentum of key brands in Oral Care, VMS, and Pain Relief; accelerating innovation in the US and China; and further growth in emerging markets. Reflecting these trends, and the investments made and planned for the business, the Board of GSK is confident that the Consumer Healthcare business can sustainably deliver annual organic sales growth in the range of 4-6% CER over the medium term. The combination of superior organic sales growth, operating margin expansion and consistent high cash generation will, we believe, offer both existing and prospective shareholders a highly attractive financial profile that facilitates continued investment in growth, the delivery of attractive returns and the opportunity of continued participation in long-term value creation. The Board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK therefore remains focused on executing its proposed demerger of the Consumer Healthcare business, to create a new independent global category-leading consumer company which, subject to approval from shareholders, is on track to be achieved in mid-2022. GSK intends to share further details of the strategy, brands, capabilities and operations, including detailed financial information and future growth ambitions for the new Consumer Healthcare business at a virtual Capital Markets Day for investors and analysts on Monday 28th February 2022."

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Hot Stocks
Unilever confirms approach made to GSK, Pfizer about GSK Consumer Healthcare » 07:42
01/15/22
01/15
07:42
01/15/22
07:42
UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

, GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

Unilever (UN, UL) has…

Unilever (UN, UL) has issued the following statement in response to press reporting: "Unilever notes recent reporting regarding its interest in GSK Consumer Healthcare and confirms that it has approached GSK and Pfizer about a potential acquisition of the business. GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio. There can be no certainty that any agreement will be reached."

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Periodicals
GSK rejected unsolicited GBP 50B bid from Unilever for consumer unit, Times says » 07:40
01/15/22
01/15
07:40
01/15/22
07:40
UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

, GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

Unilever (UN, UL) made an…

Unilever (UN, UL) made an unsolicited bid for GlaxoSmithKline's (GSK) consumer goods business worth roughly GBP 50B, which was rejected on the basis that it was too cheap, The Sunday Times' Oliver Shah and Sabah Meddings reported. Drug making giant Pfizer (PFE), which owns a minority stake in the division, was involved in the decision to decline the offer, the report noted. Reference Link

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Friday
Hot Stocks
FDA approves Pfizer's Cibinqo for moderate-to-severe atopic dermatitis » 15:33
01/14/22
01/14
15:33
01/14/22
15:33
PFE

Pfizer

$54.98 /

-0.55 (-0.99%)

Pfizer announced that the…

Pfizer announced that the United States Food and Drug Administration approved Cibinqo, an oral, once-daily, Janus kinase 1, or JAK1, inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Cibinqo is approved at the recommended doses of 100 mg and 200 mg, with the 200 mg dose being recommended for patients who are not responding to the 100 mg dose. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in patients with moderate renal impairment, certain patients receiving treatment with inhibitors of cytochrome P450 2C19, or patients who are known or suspected to be poor metabolizers of CYP2C19. For patients with moderate renal impairment who are not responding to 50 mg once daily, 100 mg once daily may also be prescribed. Cibinqo will be made available in the coming weeks, Pfizer said.

ShowHide Related Items >><<
PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

Conference/Events
Oppenheimer healthcare analysts hold an analyst/industry conference call » 14:35
01/14/22
01/14
14:35
01/14/22
14:35
AMGN

Amgen

$233.67 /

+2.75 (+1.19%)

, NVS

Novartis

$90.36 /

-0.26 (-0.29%)

, MDGL

Madrigal Pharmaceuticals

$74.95 /

-1.43 (-1.87%)

, ETNB

89bio

$11.71 /

-0.1 (-0.85%)

, VERV

Verve Therapeutics

$30.65 /

-0.27 (-0.87%)

Healthcare Analysts…

Healthcare Analysts discuss the future of cardiovascular medicine (relevant for AMGN, ETNB, MDGL, NVS and VERV) on an Analyst/Industry conference call to be held on January 21 at 9 am.

ShowHide Related Items >><<
VERV Verve Therapeutics
$30.65 /

-0.27 (-0.87%)

NVS Novartis
$90.36 /

-0.26 (-0.29%)

MDGL Madrigal Pharmaceuticals
$74.95 /

-1.43 (-1.87%)

ETNB 89bio
$11.71 /

-0.1 (-0.85%)

AMGN Amgen
$233.67 /

+2.75 (+1.19%)

AMGN Amgen
$233.67 /

+2.75 (+1.19%)

01/05/22 BofA
Amgen downgraded to Neutral from Buy at BofA
01/05/22 BofA
Amgen downgraded to Neutral from Buy at BofA
12/21/21 RBC Capital
Amgen price target raised to $218 from $216 at RBC Capital
12/08/21 Wells Fargo
Amgen initiated with an Equal Weight at Wells Fargo
NVS Novartis
$90.36 /

-0.26 (-0.29%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
MDGL Madrigal Pharmaceuticals
$74.95 /

-1.43 (-1.87%)

12/30/21 H.C. Wainwright
H.C. Wainwright sees no negative read from Madrigal's 'slight delay' for data
12/30/21 Piper Sandler
Madrigal delay for data 'no big deal,' says Piper Sandler
10/06/21 Jefferies
Madrigal Pharmaceuticals initiated with a Buy at Jefferies
08/31/21 Canaccord
Madrigal Pharmaceuticals undervalued ahead of NASH data, says Canaccord
ETNB 89bio
$11.71 /

-0.1 (-0.85%)

12/20/21
Fly Intel: Top five analyst initiations
12/20/21 H.C. Wainwright
89bio initiated with a Buy at H.C. Wainwright
11/12/21 RBC Capital
89bio price target lowered to $42 from $46 at RBC Capital
10/26/21 Cantor Fitzgerald
89bio assumed with an Overweight at Cantor Fitzgerald
VERV Verve Therapeutics
$30.65 /

-0.27 (-0.87%)

09/23/21 Stifel
Verve Therapeutics initiated with a Hold at Stifel
07/12/21 JPMorgan
Verve Therapeutics initiated with a Neutral at JPMorgan
07/12/21 Jefferies
Verve Therapeutics initiated with a Buy at Jefferies
07/12/21 Guggenheim
Verve Therapeutics initiated with a Buy at Guggenheim
VERV Verve Therapeutics
$30.65 /

-0.27 (-0.87%)

NVS Novartis
$90.36 /

-0.26 (-0.29%)

MDGL Madrigal Pharmaceuticals
$74.95 /

-1.43 (-1.87%)

ETNB 89bio
$11.71 /

-0.1 (-0.85%)

AMGN Amgen
$233.67 /

+2.75 (+1.19%)

  • 17
    Jun
NVS Novartis
$90.36 /

-0.26 (-0.29%)

AMGN Amgen
$233.67 /

+2.75 (+1.19%)

NVS Novartis
$90.36 /

-0.26 (-0.29%)

AMGN Amgen
$233.67 /

+2.75 (+1.19%)

VERV Verve Therapeutics
$30.65 /

-0.27 (-0.87%)

NVS Novartis
$90.36 /

-0.26 (-0.29%)

AMGN Amgen
$233.67 /

+2.75 (+1.19%)

Recommendations
Pfizer price target raised to $76 from $60 at BMO Capital » 06:53
01/14/22
01/14
06:53
01/14/22
06:53
PFE

Pfizer

$55.53 /

-1.11 (-1.96%)

BMO Capital analyst Evan…

BMO Capital analyst Evan Seigerman raised the firm's price target on Pfizer to $76 from $60 and keeps an Outperform rating on the shares while reiterating the stock as his Top Pick for 2022. Pfizer could be the first pharma company to break $100B revenues boosted by Paxlovid sales this year, the analyst tells investors in a research note. Seigerman adds that he estimates Paxlovid generating $30B in sales this year vs. consensus of $20B, stating that Pfizer should have the ability to use this cash flow to navigate the loss-of-exclusivity concerns.

ShowHide Related Items >><<
PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

Thursday
On The Fly
Wall Street in Fives - Must Read Lists for Thursday » 16:25
01/13/22
01/13
16:25
01/13/22
16:25
DAL

Delta Air Lines

$41.50 /

+0.92 (+2.27%)

, KBH

KB Home

$49.39 /

+7 (+16.51%)

, TSM

TSMC

$139.19 /

+6.905 (+5.22%)

, NAVI

Navient

$21.97 /

+0.07 (+0.32%)

, PFE

Pfizer

$55.53 /

-1.11 (-1.96%)

, BNTX

BioNTech

$203.07 /

-18.11 (-8.19%)

, JNJ

Johnson & Johnson

$168.78 /

-1.03 (-0.61%)

, MRNA

Moderna

$210.14 /

-12.71 (-5.70%)

, SNAP

Snap

$38.36 /

-4.385 (-10.26%)

, BMBL

Bumble

$32.50 /

-0.16 (-0.49%)

, HD

Home Depot

$386.86 /

-2.55 (-0.65%)

, BIIB

Biogen

$236.70 /

+11.38 (+5.05%)

, D

Dominion

$79.74 /

+0.435 (+0.55%)

, TSLA

Tesla

$1,031.72 /

-73.99 (-6.69%)

, GS

Goldman Sachs

$390.94 /

+0.59 (+0.15%)

, BX

Blackstone

$118.93 /

-3.36 (-2.75%)

, BYND

Beyond Meat

$70.86 /

+3.25 (+4.81%)

, NKLA

Nikola

$10.20 /

-0.235 (-2.25%)

, GRUB

Just Eat Takeaway

$10.92 /

+0.73 (+7.17%)

, DNLI

Denali Therapeutics

$33.86 /

-4.67 (-12.12%)

, SPCE

Virgin Galactic

$10.02 /

-2.345 (-18.96%)

, GRWG

GrowGeneration

$9.89 /

-1.185 (-10.70%)

, AXDX

Accelerate Diagnostics

$4.06 /

-0.2 (-4.69%)

, BGFV

Big 5 Sporting

$19.88 /

+0.29 (+1.48%)

, QTRX

Quanterix

$33.03 /

-0.08 (-0.24%)

, CVET

Covetrus

$16.49 /

-1.61 (-8.90%)

, ETWO

E2open

$8.53 /

-1.175 (-12.11%)

, BHVN

Biohaven Pharmaceutical

$122.58 /

-1.2 (-0.97%)

, AUPH

Aurinia Pharmaceuticals

$18.70 /

+0.27 (+1.47%)

, AMLX

Amylyx

$21.38 /

+0.9 (+4.39%)

Get caught up quickly on…

ShowHide Related Items >><<
TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

CVET Covetrus
$16.49 /

-1.61 (-8.90%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AXDX Accelerate Diagnostics
$4.06 /

-0.2 (-4.69%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

01/14/22 Raymond James
Delta Air Lines price target lowered to $53 from $55 at Raymond James
01/14/22 Barclays
Delta Air Lines price target lowered to $45 from $50 at Barclays
01/13/22 Goldman Sachs
Delta Air Lines price target raised to $40 from $39 at Goldman Sachs
01/13/22 Susquehanna
Delta Air Lines upgraded to Positive with $50 price target at Susquehanna
KBH KB Home
$49.39 /

+7 (+16.51%)

01/14/22 Seaport Global
KB Home downgraded to Neutral from Buy at Seaport Global
01/14/22 Raymond James
KB Home price target raised to $63 from $55 at Raymond James
01/13/22 Wedbush
KB Home price target raised to $73 from $60 at Wedbush
01/13/22 RBC Capital
KB Home price target raised to $55 from $46 at RBC Capital
TSM TSMC
$139.19 /

+6.905 (+5.22%)

01/12/22 DZ Bank
TSMC initiated with a Buy at DZ Bank
01/11/22 Cowen
TSMC price target raised to $125 from $120 at Cowen
01/11/22 New Street
New Street sees now as 'ideal timing to invest' in TSMC
11/01/21 Northland
Intel upgraded to Market Perform on new CEO's plan at Northland
NAVI Navient
$21.97 /

+0.07 (+0.32%)

01/13/22 Stephens
Stephens raises EPS estimates for Navient after state AG resolution
01/10/22 Barclays
Navient price target lowered to $25 from $26 at Barclays
01/03/22 Stephens
Navient downgraded to Equal Weight at Stephens on valuation
01/03/22 Stephens
Navient downgraded to Equal Weight from Overweight at Stephens
PFE Pfizer
$55.53 /

-1.11 (-1.96%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
MRNA Moderna
$210.14 /

-12.71 (-5.70%)

01/06/22 Argus
Moderna price target lowered to $350 from $420 at Argus
01/05/22 Piper Sandler
Piper keeps $348 target on Moderna after Epstein-Barr vaccine trial starts
12/20/21 Piper Sandler
Piper keeps Overweight rating, $348 price target on Moderna after omicron data
12/16/21 Piper Sandler
Arcturus data shows 'legit player' in COVID vaccines, says Piper Sandler
SNAP Snap
$38.36 /

-4.385 (-10.26%)

01/13/22 Cowen
Snap downgraded to Market Perform from Outperform at Cowen
01/12/22 Craig-Hallum
Craig-Hallum bullish on BuzzFeed, initiates with a Buy
01/11/22 JPMorgan
Amazon 'strong favorite' to be best performing FANG stock, JPMorgan says
12/21/21 Loop Capital
Snap price target lowered to $68 from $79 at Loop Capital
BMBL Bumble
$32.50 /

-0.16 (-0.49%)

01/12/22 Goldman Sachs
Bumble upgraded to Buy from Neutral at Goldman Sachs
01/12/22 Piper Sandler
Bumble initiated with a Neutral at Piper Sandler
12/28/21 Evercore ISI
Evercore ISI's Mark Mahaney announces top internet picks for 2022
HD Home Depot
$386.86 /

-2.55 (-0.65%)

01/12/22 Truist
Home Depot upgraded to Buy at Truist, sees market share gain potential
01/12/22 Truist
Home Depot assumed with a Buy at Truist
01/06/22 Baird
Masco may ultimately be helped by pro expansion, says Baird
01/05/22 Wells Fargo
Home Depot price target raised to $460 from $420 at Wells Fargo
BIIB Biogen
$236.70 /

+11.38 (+5.05%)

01/14/22 Jefferies
Biogen remains 'open to all options on the table,' says Jefferies
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
D Dominion
$79.74 /

+0.435 (+0.55%)

01/12/22 Goldman Sachs
Dominion downgraded to Sell from Neutral at Goldman Sachs
01/05/22 UBS
Dominion upgraded to Buy from Neutral at UBS
01/05/22 UBS
Dominion upgraded to Buy from Neutral at UBS
10/19/21 JPMorgan
Dominion settlement 'clearing event' for shares, says JPMorgan
TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

01/12/22 New Street
New Street sees 50% upside in Tesla this year amid 'perfect storm'
01/11/22 Redburn
Redburn starts Lucid Group at Neutral on risks of competing against Tesla
01/10/22 Morgan Stanley
Tesla price target raised to $1,300 from $1,200 at Morgan Stanley
01/10/22 Goldman Sachs
Goldman ups Tesla price target, says best positioned in EVs
GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

01/06/22 BofA
Goldman Sachs downgraded to Neutral from Buy at BofA
01/03/22 Barclays
Goldman Sachs price target raised to $556 from $483 at Barclays
12/06/21 Morgan Stanley
Goldman Sachs upgraded to Equal Weight at Morgan Stanley
BX Blackstone
$118.93 /

-3.36 (-2.75%)

01/13/22 Deutsche Bank
Blackstone price target lowered to $176 from $190 at Deutsche Bank
12/17/21 Deutsche Bank
Blackstone price target raised to $190 from $152 at Deutsche Bank
12/16/21 BofA
Blackstone initiated with a Buy at BofA
12/16/21 BofA
Blackstone initiated with a Buy at BofA
BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

01/05/22 BofA
Beyond Meat price target lowered to $55 from $70 at BofA
01/05/22 Piper Sandler
Piper still 'bearish' on Beyond Meat despite pending positive headline
12/14/21 BTIG
McDonald's price target raised to $295 from $255 at BTIG
12/13/21 Piper Sandler
Beyond Meat upgraded to Neutral at Piper on pending McDonald's McPlant launch
NKLA Nikola
$10.20 /

-0.235 (-2.25%)

11/08/21 Wedbush
Nikola price target raised to $15 from $10 at Wedbush
11/05/21 BTIG
Nikola downgraded to Neutral from Buy at BTIG
09/09/21 JPMorgan
Nikola price target lowered to $12 from $21 at JPMorgan
08/11/21
Fly Intel: Top five analyst initiations
GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

01/14/22 Exane BNP Paribas
Just Eat Takeaway upgraded to Neutral from Underperform at Exane BNP Paribas
01/13/22 JPMorgan
Just Eat Takeaway price target lowered to 6,285 GBp from 6,527 GBp at JPMorgan
01/13/22 Credit Suisse
Just Eat Takeaway price target lowered to 7,400 GBp at Credit Suisse
01/11/22 Morgan Stanley
Just Eat price target lowered to 7,300 GBp from 9,900 GBp at Morgan Stanley
DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

12/09/21 Raymond James
Denali Therapeutics assumed with a Market Perform at Raymond James
11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

01/14/22 Canaccord
Virgin Galactic price target lowered to $36 from $44 at Canaccord
01/13/22 Canaccord
Canaccord cuts Virgin Galactic target on offering but stays confident
10/19/21 Morgan Stanley
Virgin Galactic price target lowered to $17 from $25 at Morgan Stanley
10/18/21 UBS
Virgin Galactic downgraded to Sell from Neutral at UBS
GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

01/14/22 Craig-Hallum
GrowGeneration downgraded to Hold from Buy at Craig-Hallum
01/14/22 Stifel
GrowGeneration price target lowered to $10 from $24 at Stifel
01/14/22 Craig-Hallum
GrowGeneration downgraded to Hold from Buy at Craig-Hallum
01/13/22 Alliance Global Partners
GrowGeneration price target lowered to $20 from $35 at Alliance Global Partners
AXDX Accelerate Diagnostics
$4.06 /

-0.2 (-4.69%)

01/14/22 Craig-Hallum
Accelerate Diagnostics price target lowered to $9 from $12 at Craig-Hallum
07/07/21 Piper Sandler
Accelerate Diagnostics launches PhenoAST in the U.S., says Piper Sandler
05/10/21 Piper Sandler
Accelerate Diagnostics price target lowered to $9 from $12 at Piper Sandler
BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

08/04/21 Lake Street
Big 5 Sporting price target raised to $31 from $26 at Lake Street
05/05/21 Lake Street
Big 5 Sporting price target raised to $26 from $19 at Lake Street
03/03/21 Lake Street
Big 5 Sporting price target raised to $19 from $16 at Lake Street
QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

10/14/21 Cowen
Quanterix coverage transferred at Cowen
06/04/21
Fly Intel: Top five analyst initiations
06/04/21 Goldman Sachs
Quanterix initiated with a Sell at Goldman Sachs
05/06/21 SVB Leerink
Quanterix price target lowered to $70 from $85 at SVB Leerink
CVET Covetrus
$16.49 /

-1.61 (-8.90%)

01/12/22 Goldman Sachs
Covetrus' 2022 Rx revenue outlook may be disappointing, says Goldman Sachs
11/18/21 Morgan Stanley
Covetrus initiated with an Equal Weight at Morgan Stanley
08/04/21 Credit Suisse
Covetrus assumed with a Neutral at Credit Suisse
07/12/21 Guggenheim
Covetrus upgraded to Buy from Neutral at Guggenheim
ETWO E2open
$8.53 /

-1.175 (-12.11%)

10/11/21 Loop Capital
E2open assumed with a Buy at Loop Capital
10/11/21 Loop Capital
E2open assumed with a Buy at Loop Capital
09/30/21 BofA
E2open initiated with a Neutral at BofA
04/21/21 Loop Capital
E2open initiated with a Buy at Loop Capital
BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

01/03/22 Canaccord
Biohaven Pharmaceutical price target raised to $160 from $150 at Canaccord
12/06/21 Piper Sandler
Biohaven's zavegepant offers 'unmodeled upside,' says Piper Sandler
11/18/21 Mizuho
Biohaven Pharmaceutical price target raised to $144 from $135 at Mizuho
11/10/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $177 from $165 at Cantor Fitzgerald
AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

12/10/21 Oppenheimer
Aurinia Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
11/04/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $40 from $35 at H.C. Wainwright
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform on valuation at Oppenheimer
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
AMLX Amylyx
$21.38 /

+0.9 (+4.39%)

TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

CVET Covetrus
$16.49 /

-1.61 (-8.90%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AXDX Accelerate Diagnostics
$4.06 /

-0.2 (-4.69%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

  • 07
    Jan
  • 08
    Dec
  • 10
    Sep
  • 16
    Mar
  • 04
    Feb
  • 11
    Feb
TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

AMLX Amylyx
$21.38 /

+0.9 (+4.39%)

TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

Hot Stocks
Supreme Court allows healthcare worker vaccination rule to stand » 14:50
01/13/22
01/13
14:50
01/13/22
14:50
PFE

Pfizer

$55.66 /

-0.98 (-1.73%)

, BNTX

BioNTech

$206.90 /

-14.28 (-6.46%)

, MRNA

Moderna

$211.34 /

-11.51 (-5.16%)

, JNJ

Johnson & Johnson

$169.17 /

-0.64 (-0.38%)

The Supreme Court has…

The Supreme Court has ruled that vaccine requirements can stand for medical facilities that take Medicare or Medicaid payments, arguing that the Secretary of Health and Human Services has it within his power to mandate that, in order to receive Medicare and Medicaid funding, participating facilities must ensure that their staff-unless exempt for medical or religious reasons-are vaccinated against COVID-19. In the ruling, the high court states: "First, we agree with the Government that the Secretary's rule falls within the authorities that Congress has conferred upon him... Moreover, the Secretary routinely imposes conditions of participation that relate to the qualifications and duties of healthcare workers themselves... We accordingly conclude that the Secretary did not exceed his statutory authority in requiring that, in order to remain eligible for Medicare and Medicaid dollars, the facilities covered by the interim rule must ensure that their employees be vaccinated against COVID-19." Makers of COVID-19 vaccines approved for use in the U.S. include Pfizer (PFE) and BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ). Reference Link

ShowHide Related Items >><<
PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
MRNA Moderna
$211.34 /

-11.51 (-5.16%)

01/06/22 Argus
Moderna price target lowered to $350 from $420 at Argus
01/05/22 Piper Sandler
Piper keeps $348 target on Moderna after Epstein-Barr vaccine trial starts
12/20/21 Piper Sandler
Piper keeps Overweight rating, $348 price target on Moderna after omicron data
12/16/21 Piper Sandler
Arcturus data shows 'legit player' in COVID vaccines, says Piper Sandler
JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.